Tuberculosis specific responses following therapy for TB Impact of HIV co-infection

Tuberculosis specific responses following therapy for TB : Impact of HIV co-infection

Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 159(2015), 1 vom: 13. Juli, Seite 1-12
1. Verfasser: Siddiqui, S (VerfasserIn)
Weitere Verfasser: Sarro, Y, Diarra, B, Diallo, H, Guindo, O, Dabitao, D, Tall, M, Hammond, A, Kassambara, H, Goita, D, Dembele, P, Traore, B, Hengel, R, Nason, M, Warfield, J, Washington, J, Polis, M, Diallo, S, Dao, S, Koita, O, Lane, H C, Catalfamo, M, Tounkara, A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2015
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Intramural CD4+ T cells HIV Tuberculosis Anti-HIV Agents Antigens, Bacterial Antitubercular Agents HLA-DR Antigens IL10 protein, human mehr... IL2 protein, human Interleukin-13 Interleukin-2 Tumor Necrosis Factor-alpha Interleukin-10 130068-27-8 Mycobacterium tuberculosis antigens 144058-44-6 Interleukin-12 187348-17-0 Interferon-gamma 82115-62-6 ADP-ribosyl Cyclase 1 EC 3.2.2.6
LEADER 01000naa a22002652 4500
001 NLM248205323
003 DE-627
005 20231224150910.0
007 cr uuu---uuuuu
008 231224s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2015.04.002  |2 doi 
028 5 2 |a pubmed24n0827.xml 
035 |a (DE-627)NLM248205323 
035 |a (NLM)25889622 
035 |a (PII)S1521-6616(15)00132-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Siddiqui, S  |e verfasserin  |4 aut 
245 1 0 |a Tuberculosis specific responses following therapy for TB  |b Impact of HIV co-infection 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 24.08.2015 
500 |a Date Revised 16.11.2017 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Published by Elsevier Inc. 
520 |a Characterizing perturbations in the immune response to tuberculosis in HIV can develop insights into the pathogenesis of coinfection. HIV+ TB+ and TB monoinfected (TB+) subjects recruited from clinics in Bamako prior to initiation of TB treatment were evaluated at time-points following initiation of therapy. Flow cytometry assessed CD4+/CD8+ T cell subsets and activation markers CD38/HLA-DR. Antigen specific responses to TB proteins were assessed by intracellular cytokine detection and proliferation. HIV+ TB+ subjects had significantly higher markers of immune activation in the CD4+ and CD8+ T cells compared to TB+ subjects. HIV+ TB+ had lower numbers of TB-specific CD4+ T cells at baseline. Plasma IFNγ levels were similar between HIV+ TB+ and TB+ subjects. No differences were observed in in-vitro proliferative capacity to TB antigens between HIV+ TB+ and TB+ subjects. Subjects with HIV+ TB+ coinfection demonstrate in vivo expansion of TB-specific CD4+ T cells. Immunodeficiency associated with CD4+ T cell depletion may be less significant compared to immunosuppression associated with HIV viremia or untreated TB infection 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Intramural 
650 4 |a CD4+ T cells 
650 4 |a HIV 
650 4 |a Tuberculosis 
650 7 |a Anti-HIV Agents  |2 NLM 
650 7 |a Antigens, Bacterial  |2 NLM 
650 7 |a Antitubercular Agents  |2 NLM 
650 7 |a HLA-DR Antigens  |2 NLM 
650 7 |a IL10 protein, human  |2 NLM 
650 7 |a IL2 protein, human  |2 NLM 
650 7 |a Interleukin-13  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Mycobacterium tuberculosis antigens  |2 NLM 
650 7 |a 144058-44-6  |2 NLM 
650 7 |a Interleukin-12  |2 NLM 
650 7 |a 187348-17-0  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a ADP-ribosyl Cyclase 1  |2 NLM 
650 7 |a EC 3.2.2.6  |2 NLM 
700 1 |a Sarro, Y  |e verfasserin  |4 aut 
700 1 |a Diarra, B  |e verfasserin  |4 aut 
700 1 |a Diallo, H  |e verfasserin  |4 aut 
700 1 |a Guindo, O  |e verfasserin  |4 aut 
700 1 |a Dabitao, D  |e verfasserin  |4 aut 
700 1 |a Tall, M  |e verfasserin  |4 aut 
700 1 |a Hammond, A  |e verfasserin  |4 aut 
700 1 |a Kassambara, H  |e verfasserin  |4 aut 
700 1 |a Goita, D  |e verfasserin  |4 aut 
700 1 |a Dembele, P  |e verfasserin  |4 aut 
700 1 |a Traore, B  |e verfasserin  |4 aut 
700 1 |a Hengel, R  |e verfasserin  |4 aut 
700 1 |a Nason, M  |e verfasserin  |4 aut 
700 1 |a Warfield, J  |e verfasserin  |4 aut 
700 1 |a Washington, J  |e verfasserin  |4 aut 
700 1 |a Polis, M  |e verfasserin  |4 aut 
700 1 |a Diallo, S  |e verfasserin  |4 aut 
700 1 |a Dao, S  |e verfasserin  |4 aut 
700 1 |a Koita, O  |e verfasserin  |4 aut 
700 1 |a Lane, H C  |e verfasserin  |4 aut 
700 1 |a Catalfamo, M  |e verfasserin  |4 aut 
700 1 |a Tounkara, A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 159(2015), 1 vom: 13. Juli, Seite 1-12  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:159  |g year:2015  |g number:1  |g day:13  |g month:07  |g pages:1-12 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2015.04.002  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 159  |j 2015  |e 1  |b 13  |c 07  |h 1-12